PT101702A - Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima - Google Patents

Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima Download PDF

Info

Publication number
PT101702A
PT101702A PT101702A PT10170295A PT101702A PT 101702 A PT101702 A PT 101702A PT 101702 A PT101702 A PT 101702A PT 10170295 A PT10170295 A PT 10170295A PT 101702 A PT101702 A PT 101702A
Authority
PT
Portugal
Prior art keywords
tumor cells
proficks
benzima
anticorpo
conjugates
Prior art date
Application number
PT101702A
Other languages
English (en)
Other versions
PT101702B (pt
Inventor
Mark G Saulnier
Peter D Senter
David E Kerr
Joseph Patric Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT101702A publication Critical patent/PT101702A/pt
Publication of PT101702B publication Critical patent/PT101702B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT101702A 1987-08-04 1995-05-12 Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima PT101702B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US16106888A 1988-02-26 1988-02-26
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (2)

Publication Number Publication Date
PT101702A true PT101702A (pt) 1996-01-31
PT101702B PT101702B (pt) 1999-11-30

Family

ID=27373967

Family Applications (2)

Application Number Title Priority Date Filing Date
PT88187A PT88187B (pt) 1987-08-04 1988-08-03 Processo para a preparacao de conjugados anticorpo-enzima em associacao com profarmacos para a libertacao de agentes citotoxicos em celulas tumorais
PT101702A PT101702B (pt) 1987-08-04 1995-05-12 Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT88187A PT88187B (pt) 1987-08-04 1988-08-03 Processo para a preparacao de conjugados anticorpo-enzima em associacao com profarmacos para a libertacao de agentes citotoxicos em celulas tumorais

Country Status (19)

Country Link
EP (2) EP0540859B1 (pt)
JP (2) JP2738414B2 (pt)
KR (1) KR930006757B1 (pt)
AT (2) ATE162196T1 (pt)
AU (1) AU614532B2 (pt)
CA (1) CA1336887C (pt)
DE (2) DE3856112T2 (pt)
DK (1) DK175406B1 (pt)
EG (1) EG18751A (pt)
ES (1) ES2068191T3 (pt)
FI (1) FI98197C (pt)
GR (1) GR3015065T3 (pt)
HU (1) HU207230B (pt)
IE (2) IE68309B1 (pt)
IL (1) IL87319A (pt)
NO (1) NO178138C (pt)
NZ (1) NZ225599A (pt)
PT (2) PT88187B (pt)
YU (1) YU150888A (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
KR0185967B1 (ko) * 1989-01-23 1999-05-01 에프. 쥐. 엠. 헤르만스; 에이. 쥐. 제이. 베르미렌 치료용 약물의 부위 특이적 생체내 활성작용
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
EP0505357B1 (en) * 1989-12-11 1999-03-10 Immunomedics, Inc. Method for antibody targeting of diagnostic or therapeutic agents
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
KR920007937B1 (ko) * 1990-01-30 1992-09-19 현대자동차 주식회사 밸브시트용 철(Fe)계 소결합금
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
KR100208957B1 (ko) * 1990-04-25 1999-07-15 로렌스 티. 마이젠헬더 신규한 cc-1065 유사체
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
DE60237915D1 (en) * 2001-12-03 2010-11-18 Universitaetsklinikum Charite Podophyllotoxine als antiproliferative mittel
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1735350B1 (en) * 2004-04-15 2010-08-25 Genencor International, Inc. Anti-cea scfv - beta-lactamase constructs (cab molecules) in adept
WO2008024103A1 (en) * 2006-08-21 2008-02-28 Essential Skincare, Llc Compositions to reduce or prevent skin cancer
CN112272673A (zh) * 2018-01-04 2021-01-26 上海晟顺生物科技有限公司 单域抗体-胞嘧啶脱氨酶融合蛋白

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (pt) * 1967-11-28 1969-08-22
FR2122695A5 (en) * 1971-01-20 1972-09-01 Rhone Poulenc Sa Antibiotics duborimycin and 27706rp - by reduction of daunorubicin and adriamycin
FR2397425A1 (fr) 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
CA1168150A (en) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (en) 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutic substance for treating diseases such as cancer
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
EP0202245A1 (en) * 1984-11-23 1986-11-26 Sri International C-glycosidic adriamycin analogs
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
DE3500023A1 (de) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-desoxyanthracyclinester
FR2584294B1 (fr) 1985-07-08 1992-02-21 Berdal Pascal Compositions pharmaceutiques a visee cytotrophique
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems

Also Published As

Publication number Publication date
GR3015065T3 (en) 1995-05-31
ATE162196T1 (de) 1998-01-15
NO178138C (no) 1996-01-31
JPH02223532A (ja) 1990-09-05
KR930006757B1 (ko) 1993-07-23
NO883414D0 (no) 1988-08-02
EP0302473B1 (en) 1995-02-15
JPH10130295A (ja) 1998-05-19
HU207230B (en) 1993-03-29
ES2068191T3 (es) 1995-04-16
PT101702B (pt) 1999-11-30
JP3127136B2 (ja) 2001-01-22
IL87319A0 (en) 1990-02-09
DE3853028D1 (de) 1995-03-23
ATE118354T1 (de) 1995-03-15
NZ225599A (en) 1991-09-25
EP0302473A3 (en) 1990-01-17
PT88187A (pt) 1989-06-30
NO178138B (no) 1995-10-23
NO883414L (no) 1989-02-06
EP0540859A1 (en) 1993-05-12
IE882379L (en) 1989-02-04
IL87319A (en) 1995-08-31
FI98197B (fi) 1997-01-31
AU2020188A (en) 1989-05-25
EP0302473A2 (en) 1989-02-08
DK434188D0 (da) 1988-08-03
DE3853028T2 (de) 1995-12-14
JP2738414B2 (ja) 1998-04-08
DK434188A (da) 1989-02-05
EG18751A (en) 1993-12-30
EP0540859B1 (en) 1998-01-14
FI98197C (fi) 1997-05-12
DE3856112T2 (de) 1998-08-27
DE3856112D1 (de) 1998-02-19
FI883597A (fi) 1989-02-05
KR890003408A (ko) 1989-04-14
DK175406B1 (da) 2004-09-27
PT88187B (pt) 1995-12-29
YU150888A (en) 1990-06-30
FI883597A0 (fi) 1988-08-01
IE950981L (en) 1989-02-04
IE68309B1 (en) 1996-06-12
CA1336887C (en) 1995-09-05
HUT47437A (en) 1989-03-28
AU614532B2 (en) 1991-09-05

Similar Documents

Publication Publication Date Title
PT101702A (pt) Processo para a preparacao de profarmacos antraciclinicos e de composicoes e de associacoes farmaceuticas que os contem ligados a conjugados anticorpo-benzima
DE3853792T2 (de) Amin-Derivate von Anthracyclin-Antibiotika.
FI890599A (fi) Antracyklin-immunokonjugater med ny linker och foerfarande foer deras producering.
GB9026397D0 (en) Immunoconjugates and prodrugs and their use in association for drug delivery
PL307226A1 (en) Derivatives of nitrous yperite and amino acid and their application as ancillary drug in treating neoplasms
SE8504945D0 (sv) Pharmaceutical compositions containing anthracycline glycosides
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
PT94064A (pt) Processo para a preparacao de novos conjugados de antraciclina que comportam um novo ligante e de composicoes farmaceuticas que os contem
EP0745390A3 (en) Polymeric prodrugs for beta-lactamase and uses thereof
MY103598A (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.
DK328189D0 (da) Konjugater mellem et laegemiddel og en nitrophenylgruppe samt farmaceutisk anvendelse deraf

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19950922

FG3A Patent granted, date of granting

Effective date: 19990802

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20001130